<i>In vitro</i> antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19Carolina Q. Sacramento, Thiago Moreno L. Souza, Camila R. R. Pão et al.|Journal of Antimicrobial Chemotherapy|2021Cited by 104
Human endogenous retrovirus K in the respiratory tract is associated with COVID-19 physiopathologyJairo R. Temerozo, Thiago Moreno L. Souza, Natalia Fintelman‐Rodrigues et al.|Microbiome|2022Cited by 38
The <i>in vitro</i> antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2Carolina Q. Sacramento, Thiago Moreno L. Souza, Natalia Fintelman‐Rodrigues et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 37
Genetic Evidence and Host Immune Response in Persons Reinfected with SARS-CoV-2, BrazilNatalia Fintelman‐Rodrigues, Thiago Moreno L. Souza, Aline de Paula Dias da Silva et al.|Emerging infectious diseases|2021Cited by 26